Krystal Biotech, Inc.: insider trades · United States · SEC (Form 4)

About Krystal Biotech, Inc.

Krystal Biotech, Inc. is a U.S.-based biotechnology company listed on the NASDAQ in the United States, with headquarters in Pittsburgh, Pennsylvania. Founded originally as Krystal Biotech, LLC and later reorganized as a corporation in 2017, the company has been built around a proprietary platform using modified, replication-defective, non-integrating HSV-1 vectors. Its core strategy is to develop redosable gene therapies for severe rare diseases with limited or no approved treatment options. For investors, Krystal represents a specialized, science-driven biotech with a vertically integrated model that combines R&D, manufacturing, and selective commercialization. ([krystalbio.com](https://www.krystalbio.com/?utm_source=openai)) Krystal’s commercial anchor is VYJUVEK (beremagene geperpavec-svdt, or B-VEC), approved for dystrophic epidermolysis bullosa (DEB). The company describes VYJUVEK as its first commercial product and the first redosable gene therapy approved in major jurisdictions including the United States, Europe, and Japan. That makes Krystal unusual among small- to mid-cap biotech names: it is no longer a pure development-stage story, but a commercial rare-disease company with an established revenue base and an expanding global footprint. ([ir.krystalbio.com](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-first-quarter-2026-financial-and?utm_source=openai)) Competitively, Krystal’s edge comes from product differentiation and platform depth rather than scale. VYJUVEK’s commercial progress has given the company an early-mover position in DEB, while the broader pipeline provides optionality across dermatology, oncology, and other rare or genetically defined conditions. Krystal also operates two GMP facilities, which supports manufacturing control and may reduce reliance on third parties as demand scales. For investors, this vertical integration is important because it can improve supply resilience and operational visibility, although execution risk remains typical of specialty biotech. ([krystalbio.com](https://www.krystalbio.com/?utm_source=openai)) Geographically, the company is anchored in Pittsburgh but increasingly international in ambition. In 2025 and 2026, Krystal highlighted ongoing commercialization of VYJUVEK in the United States, Europe, and Japan, and described a specialty-distributor network covering additional regions such as the Middle East, Turkey, and Central and Eastern Europe. The implication is clear: management is building a global rare-disease franchise rather than relying solely on the U.S. market. ([ir.krystalbio.com](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-third-quarter-2025-financial-and?utm_source=openai)) Recent developments have been constructive. In early 2026, Krystal reported strong VYJUVEK revenue growth and reiterated the strength of its balance sheet, while also pointing to multiple pipeline catalysts. Management highlighted expected 2026 readouts for KB803 and KB801, and the FDA granted platform technology designations for KB407 and KB111. The company also received RMAT designation for KB707 in advanced or metastatic non-small cell lung cancer, underscoring that the platform is being extended beyond dermatology. For a Form 4-driven investor audience, these updates matter because insider activity should be interpreted alongside commercial momentum, pipeline execution, and the company’s ability to convert scientific credibility into additional approved products. ([ir.krystalbio.com](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-first-quarter-2026-financial-and?utm_source=openai))